AstraZeneca and Daiichi Sankyo reach clinical milestone in Phase 3 Trial of Datopotamab Deruxtecan compared to chemotherapy for Lung Cancer

CAR-T Digest - August 2020

Weekly Digest - June 2024

5 June 2024: AstraZeneca and Daiichi Sankyo reach clinical milestone in Phase 3 Trial of Datopotamab Deruxtecan compared to chemotherapy for Lung Cancer

TROPION-Lung01 Phase III trial results show that datopotamab deruxtecan (Dato-DXd) significantly improves overall survival compared to chemotherapy in patients with advanced NSCLC
The study evaluated the efficacy and safety of Dato-DXd versus docetaxel in NSCLC patients with and without actionable genomic alterations requiring systemic therapy after prior treatment
Dato-DXd is a novel ADC targeting TROP2, a protein broadly expressed in most NSCLC tumors
Dato-DXd also demonstrates favorable safety profile with manageable side effects
If approved by regulatory authorities, Dato-DXd could potentially become a new SOC for patients with this difficult-to-treat lung cancer